The Biden administration announced on Monday that it would buy 3.2 million doses of a Covid-19 vaccine from the Maryland pharmaceutical company Novavax that is expected to soon receive authorization in the United States.
Novavax is expected to start delivering COVID-19 vaccine doses to the European Union in the first quarter 2022, according to a report from Reuters.
Novavax Inc has enrolled the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373.
